Greg Brown
InvestorAdvisory Board - Healthcare Royalty Investing Pioneer at FemHealth Ventures
Houston, Texas, United States
About
Gregory B. Brown, M.D. is CEO and a director of Memgen, Inc., a development-stage company working on next-generation viral immunotherapeutics including oncolytic viruses. He co-founded HCR Partners, a healthcare-focused asset management firm, and was previously a partner at Paul Capital Partners where he co-managed royalty investments; earlier he was co-head of investment banking and head of healthcare at Adams, Harkness & Hill and a biotechnology research analyst at Vector Securities International. Trained as a transplantation immunologist and thoracic and vascular surgeon, he holds a B.A. from Yale College, an M.D. from SUNY Upstate Medical Center, and an M.B.A. from Harvard Business School.
Invests in
BiotechHealthtechMedical Devices
Experience
- Bering CapitalAdvisorcurrent2025 — present
- AdimabDirector, ARC Boardcurrent2024 — presentLebanon, NH
- FemHealth VenturesAdvisory Boardcurrent2022 — present
- Gordian Group, LLCSenior Advisorcurrent2020 — presentNew York, NY
- Lisata Therapeutics, Inc.Chairman Of The Boardcurrent2016 — presentBasking Ridge, New Jersey, United States
- Aquestive TherapeuticsChairman of the Boardcurrent2007 — presentWarren, New Jersey, United States
- HealthCare Royalty PartnersFounder & Member, Senior Advisor Board2007 — 2026Stamford, CT
- MemgenChief Executive Officer2020 — 2026Houston, Texas
- Faron Pharmaceuticals, OyDirector2017 — 2023Turku Metropolitan Area
- FAST BioMedicalDirector2020 — 2022Indianapolis, Indiana, United States
- Paul Capital PartnersPartner2003 — 2006
- Adams, Harkness & HillManaging Director1997 — 2002
- Vector Securities International Inc.Vice President1992 — 1997
- MerckSummer Associate1991
- MerckSummer Associate1991
- MerckSummer Associate1991
- Max, DeTraglia, Brown & Max, P.C.Partner1984 — 1990
- S.U.N.Y. Upstate Medical CenterSurgical Resident1979 — 1984
Investments
Board seats
Aquestive Therapeutics, Inc.Caladrius Biosciences, Inc.Faron Pharmaceuticals OyFAST BioMedicalMemgen, Inc
Per the firm's website.
Colleagues at FemHealth Ventures
Frequently asked questions
- Who is Greg Brown?
- Gregory B. Brown, M.D. is CEO and a director of Memgen, Inc., a development-stage company working on next-generation viral immunotherapeutics including oncolytic viruses. He co-founded HCR Partners, a healthcare-focused asset management firm, and was previously a partner at Paul Capital Partners where he co-managed royalty investments; earlier he was co-head of investment banking and head of healthcare at Adams, Harkness & Hill and a biotechnology research analyst at Vector Securities International. Trained as a transplantation immunologist and thoracic and vascular surgeon, he holds a B.A. from Yale College, an M.D. from SUNY Upstate Medical Center, and an M.B.A. from Harvard Business School.
- Where does Greg Brown work?
- Greg Brown is Advisory Board - Healthcare Royalty Investing Pioneer at FemHealth Ventures.
- What does Greg Brown invest in?
- Greg Brown invests in Biotech, Healthtech, Medical Devices.
- What boards does Greg Brown sit on?
- Greg Brown holds tracked board seats at Aquestive Therapeutics, Inc., Caladrius Biosciences, Inc., Faron Pharmaceuticals Oy, FAST BioMedical, Memgen, Inc.
- Where did Greg Brown go to school?
- Greg Brown studied at Harvard Business School (MBA); Upstate Medical University (MD); Yale University (A.B.).
Same school
Also attended Harvard Business School2,000
+ 1,994 more
